Carlos Oltmanns

Hannover | 28 | MD | Physician🩺 | Scientist🦠🧬🔬

[Carlos Oltmanns @crls_olt]

Happy to receive this year’s doctoral thesis award of the Northern German Association of Gastroenterologists (NDGG)🩺🧪🎓🎉

[Carlos Oltmanns @crls_olt]

Dr. med.✅

[Carlos Oltmanns @crls_olt]

Soluble immune mediators, that were associated with HBV activity affected pathways such as JAK-STAT and the Th17/IL-17 axis, both closely linked to fibrogenesis and liver cirrhosis.

[Carlos Oltmanns @crls_olt]

Happy to see some of our recent findings now published in JVH📚.
🔬We show how soluble immune mediators are expressed when two
🦠chronic viral infections meet each other in a human host and how they are affected when
💪 viral dominance comes into play.

https://t.co/KytbEaWeG5

[Carlos Oltmanns @crls_olt]

The exact mechanisms behind the interplay of both viruses remain elusive and need further investigation.

[Carlos Oltmanns @crls_olt]

We now demonstrate that HBV activity seems to play a major role in this condition, regardless of the usual consideration as a stealth virus. HBV activity was in our study associated with higher expression of soluble immune mediators.

[Carlos Oltmanns @crls_olt]

It has been shown before that coinfection expresses different dominance patterns with HBV and/or HCV being the dominant infections.

[Carlos Oltmanns @crls_olt]

It is rare to be able to study two chronic infections in a human host at the same time. HBV/HCV is still vastly understudied and information limited.

[Carlos Oltmanns @crls_olt]

HBV and HCV coinfection is a rare condition, especially prevalent in high risk groups for infection. It goes along with an even higher cirrhosis risk than each mono infection on its own.

[Carlos Oltmanns @crls_olt]

Happy to share some of the findings of my doctoral thesis during this year's @MHH_life Science Slam.
Thanks @MHHumor for bringing this event to the campus, great to see Lecture Hall F this packed...

[Maasoumy_liverlab @Maasoumy_lab]

This years research group retreat in collaboration with @labCornbergKraf featured:

- 10 research presentations🩺
- progress reports on our prospective studies📈
- countless discussions & ideas💡
- sunset BBQ ☀️
- Power Point karaoke 🥳

Some impressions below #livertwitter

[CiiM, Centre for Individualised Infection Medicine @Helmholtz_CiiM]

Today it was time for the last nails during the topping-out ceremony of CiiM, a joint initiative of @helmholtz_hzi and @MHH_life, realized with funds from @BMBF_Bund, Lower Saxony's Minister for Science and Culture (MWK) and @helmholtz_de.

[Moana Witte @MoanaWitte]

Had a great time in #Milano at #EASL2024 presenting our newest data about the soluble inflammatory mileu in chronic HCV patients developing HCC
#HCC #HCV #Inflammation

[LabCornbergKraft @labCornbergKraf]

#EASL2024 was an absolute blast! 🥳 Thanks so much for having us and for the amazing opportunity to present our research in #viralhepatitis 👩‍🔬👨‍🔬

[Maasoumy_liverlab @Maasoumy_lab]

Many thanks @EASLnews - We had a wonderful time at #EASL2024!

💪 7 #team members with 8 posters
🎤 2 poster tours
🥇 1 top poster
🍕 Many inspiring discussions & lots of pizza

Ciao #Milano! See you in Amsterdam next year!

[Carlos Oltmanns @crls_olt]

Great day to have a poster presentation @EASLnews Congress 2024:
Shared our recent data on HBV/HCV coinfection🦠🩺🔬🖥️
-Inflammatory cytokine milieu was associated with HBV activity in our retrospective cohort study
-Altered Cytokines were linked to fibrosis and carcinogenesis

[Carlos Oltmanns @crls_olt]

💡The search for a predictive HCC biomarker continues. Novel multidimensional approaches combining biomarkers and clinical characteristics might improve results based on machine learning algorithms. But validation in real world cohorts is lacking and needs further investigation.

[Carlos Oltmanns @crls_olt]

🦠🔬 S2-bound α1-acid glycoprotein a promising marker to predict HCC after HCV cure? Results from our recent phase 3 bio marker trial @MHH_life in collaboration with @liu_universitet & @karolinskainst

https://t.co/cZrFoeJVHK

[Carlos Oltmanns @crls_olt]

💊Treatment of HCV led to a decrease of S2-bound AGP. Additionally, S2-bound AGP levels were associated with liver fibrosis and inflammation. Patients with chronic hepatitis B virus infection and metabolically associated steatotic liver disease showed low levels of S2-bound AGP.